Feasibility Study: Curcumin; A clinical trial for gout in Samoa

Using the Samoa population, a feasibility study investigating the effect of curcumin on gout symptoms such as serum urate and gout flare

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12622001073796

Acronym

CGT

Enrollment

Registered

2022-08-03

Start date

2021-12-06

Completion date

2022-01-03

Last updated

2022-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study is a feasibility study on the efficacy of curcumin on gout symptoms (i.e., serum urate and gout flare occurrence). This feasibility study addresses issues identified to be potential factors that could affect the future study. It is hypothesized that curcumin will reduce serum urate levels and reduce the frequency of gout flares in gout patients.

Interventions

500mg curcumin capsule administered orally once per day for 3 months. Adherence will be monitored during each visit using pill counts.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

17 Years to 80 Years

Healthy volunteers

Inclusion criteria

• Existing serum urate of greater than or equal to 0.36 mmol/L • At least 1 gout flare in the last 6 months • Capable of providing informed consent and having provided it • Aged between 17 and 80 years • Gout, according to the 2015 ACR/EULAR classification criteria • Samoan ethnicity

Exclusion criteria

• Severe health issues with poor prognosis (e.g. people on dialysis) • Severe renal impairment eGFR < 30ml/minutes • Renal transplant • Cancer • Plans to move out of the area within the next 3 months • Diagnosis with other inflammatory arthritis • Current consumer of turmeric products

Outcome results